. 2021 Feb 18;18(8):1786–1797. doi: 10.7150/ijms.46811

Table 3.

Subgroup analysis of overall response and adverse events for RRMM with CAR-T

Subgroups	Overall Response				Grade 3-4 rates of CRS				NT
Subgroups	Patients (n/N)	Pooled proportion	95% CI	p-interaction	Patients (n/N)	Pooled proportion	95% CI	p-interaction	Patients (n/N)	Pooled proportion	95% CI	p-interaction
Country				<0.05				>0.05				<0.05
Eastern	156/181	86	76-92		23/187	14	8-24		4/117	6	2-13
Western	118/169	69	56-79		20/160	14	8-23		33/160	23	15-34
Trial site				>0.05				>0.05				>0.05
Single center	113/151	75	60-86		22/157	13	7-23		11/104	10	4-23
Multiple center	161/199	80	66-88		21/190	15	9-25		26/173	15	7-29
Trial status				>0.05				>0.05				>0.05
Completed	107/141	72	51-86		18/131	17	9-30		9/114	10	4-25
Ongoing	167/209	80	68-88		25/216	14	8-21		28/163	15	8-27
scFvs origin				>0.05				>0.05				>0.05
Human	61/84	74	53-87		11/84	14	6-27		12/75	16	6-35
Non-human	190/228	83	72-90		28/225	14	8-23		25/169	14	6-28
Co-stimulatory domain			>0.05				>0.05				>0.05
4-1BB	209/256	81	71-89		28/260	12	7-19		31/218	13	7-24
CD28	45/61	72	45-90		10/51	21	8-44		6/23	25	5-66
CARs				>0.05				>0.05				>0.05
2^nd generation	254/322	78	68-86		38/316	14	9-20		37/246	15	9-25
3^rd generation	10/16	65	26-91		1/19	8	1-37		0/19	5	1-33
Antigen target				<0.05				>0.05				>0.05
BCMA	223/274	82	72-89		37/268	16	10-23		35/198	19	11-31
Non-BCMA	11/27	43	18-72		0/27	7	2-25		0/27	7	1-26
CAR-T regimen				<0.05				>0.05				>0.05
Anti-BCMA contained	266/323	81	73-88		43/320	15	10-22		37/250	15	9-25
Anti-BCMA uncontained	11/27	43	18-72		0/27	7	2-25		0/27	7	1-27
CAR-T therapy mode				>0.05				>0.05				>0.05
Single-target	234/301	77	66-85		37/295	14	9-21		35/225	16	10-27
Dual-target	40/49	80	55-93		6/52	14	5-34		2/52	6	2-21